Now showing items 1-3 of 3

    • A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells 

      Duan, Zhenfeng; Zhang, Jianming; Ye, Shunan; Shen, Jacson; Choy, Edwin; Cote, Gregory; Harmon, David; Mankin, Henry; Hua, Yingqi; Zhang, Yu; Gray, Nathanael S; Hornicek, Francis J (BioMed Central, 2014)
      Background: Reversing multidrug resistance (MDR) has been an important goal for clinical and investigational oncologists. In the last few decades, significant effort has been made to search for inhibitors to reverse MDR ...
    • CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcoma 

      Gao, Yan; Feng, Yong; Shen, Jacson K.; Lin, Min; Choy, Edwin; Cote, Gregory M.; Harmon, David C.; Mankin, Henry J.; Hornicek, Francis J.; Duan, Zhenfeng (Nature Publishing Group, 2015)
      Osteosarcoma is the most common primary bone malignancy in children and adolescents. Herein, we investigated the role of cluster of differentiation 44 (CD44), a cell-surface glycoprotein involved in cell-cell interactions, ...
    • Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy 

      Choy, Edwin; Butrynski, James E; Harmon, David C; Morgan, Jeffrey A; George, Suzanne; Wagner, Andrew J; D’Adamo, David; Cote, Gregory M; Flamand, Yael; Benes, Cyril H; Haber, Daniel A; Baselga, Jose M; Demetri, George D (BioMed Central, 2014)
      Background: Preclinical studies have documented antitumor activity of PARP inhibition both in vitro and in vivo, against Ewing sarcoma cells. This study aimed to translate that observation into a clinical trial to assess ...